Cisbio international Announces Launch of HTRF<sup>®</sup> KinEASE™ TK at SBS
16 Apr 2007Product news
Cisbio international, a global developer of HTRF® technology and services used in assay development and drug screening, announced the launch of HTRF® KinEASE™ TK today at the SBS Conference in Montreal, Canada. HTRF® KinEASE™ TK is a universal and sensitive assay for high throughput screening of Tyrosine (Tyr) kinases, major targets in drug discovery, in particular in oncology research. With the development of this new tool, Cisbio now offers its customers the ability to use a reliable and sensitive kinase screening platform based on one technology to address a broad range of kinase targets.
HTRF® KinEASE™ TK combines a peptide substrate called S4 and a single, proprietary monoclonal antibody with Cisbio’s HTRF® (homogeneous time resolved fluorescence) technology, a highly sensitive, robust technology for the detection of molecular interactions of proteins in vitro. HTRF® KinEASE™ TK limits assay development time and is easily miniaturizable and flexible, meaning the assay can be performed under a wide range of kinase assay conditions, for instance with low consumption of enzyme or with any ATP concentration.
HTRF® KinEASE™ TK is the fifth kit in the HTRF® KinEASE™ platform, developed in collaboration with Millipore (Upstate) for profiling and HTS of Serine/Threonine (Ser/Thr) kinases. Launched in March 2006, the platform consists of four kits combining 3 biotinylated substrates, S1, S2 and S3, with a monoclonal antibody and HTRF®. Since this new Tyr kinase assay is based on the same monoclonal antibody principle as HTRF® KinEASE™, the implementation of the assay by Cisbio’s existing HTRF® KinEASE™ customers is very straightforward.
“With the addition of HTRF® KinEASE™ TK to our kinase assay portfolio, Cisbio has now developed a rich kinase screening platform that has been validated on over 160 kinases,” said François Degorce, head of HTRF® marketing & business development at Cisbio international. “Developing this monoclonal antibody-based kit to address Tyrosine kinases is testimony to our ongoing commitment to anticipate our customers’ needs and provide them with easy-to-use, reliable, and sensitive assay development tools.”
Cisbio complements its kinase screening platform with a comprehensive line of toolbox reagents and custom labeling and assay development services for the creation of highly specific Ser/Thr and Tyr kinase assays. Cisbio enables its customers to use a single technology, HTRF®, for both universal and specific kinase assays, saving valuable development time and cost.